Image source: Geneva University Hospitals (HUG)

Watson on the case

Personalised cancer care through AI

The Geneva University Hospitals (HUG) is the first European university hospital to utilize IBM’s artificial intelligence (AI) technology to help uncover therapeutic options for cancer patients.

HUG will use the IBM Watson Health’s precision oncology offering, Watson for Genomics, an AI tool that enables oncologists to provide patients with more personalized, evidence-based cancer care. Using information extracted from peer-reviewed articles and validated by experts, Watson for Genomics produces a report for physicians classifying genetic alterations in a patient’s tumor and providing associated therapies and clinical trials for the actionable ones. By implementing this tool, physicians at HUG are able to more quickly categorize massive bodies of genomic data for various cancer types and scale precision oncology for their patients.

Recommended article

Photo

A look into the crystal ball

Experts debate predictive potential of AI

‘Hello, John? You are about to suffer a heart attack – please come to the hospital immediately!’ Will we, one day, be collected by emergency doctors even before we’re ill? If it was up to some AI experts at Medica, this could be the case – soon. Some obstacles must yet be overcome to achieve perfect AI predictions. Yet, during Medica, some IT experts ventured to gaze into a crystal ball.

This technology provides clinicians the ability to find actionable genomic insights that manual interpretation may miss while also saving clinician time

Nathan Levitan

“As the first European hospital to adopt Watson for Genomics we will further help our physicians provide more personalized cancer care and streamline variability for genomic reporting, which we believe may improve outcomes for our patients,” said Rodolphe Meyer M.D., Deputy Chief Information Officer at HUG. “We remain very committed to the fight against cancer, including utilizing the best technological advances in medicine, such as AI, and participating in ongoing, quality academic research”. With 18 million diagnoses each year (according to the WHO cancer fact sheet), cancer has a heavy human toll, as well as a high health system cost. Patients can face exhausting, lengthy and confusing treatment regimens, while oncologists are responsible for staying up to date on an ever-growing body of medical literature and genomic data to identify the best care plan for each individual patient. “We are pleased to partner with Geneva University Hospitals, and we are pleased to work with HUG to help their physicians focus on what matters most – their patients – and help them make more informed decisions that aid in their treatment and care, says Nathan Levitan, M.D., Chief Medical Officer Oncology & Genomics, IBM Watson Health. “This technology provides clinicians the ability to find actionable genomic insights that manual interpretation [Kim et al., Journal of Clinical Oncology 2019] may miss while also saving clinician time – completing classification of gene and RNA-sequencing results in ten minutes compared to what would take 160 hours manually.” [Wrzeszczynski et al, Neurology Genetics 2017]


Source: Geneva University Hospitals (HUG)

12.09.2019

Read all latest stories

Related articles

Photo

MEDICA 2013

Genetically targeted medicine forges ahead

Healthcare is undergoing a major change set to offer a real prospect of far more genetically targeted treatments, according a leading human geneticist Sir John Burn, Professor of Clinical Genetics at…

Photo

Methods, quality assurance, commercial providers issues

Molecular testing takes a huge leap

In terms of success in revolutionary cancer treatment, molecular genetic examination procedures have developed immensely over recent years. They now range from conventional polymerase chain reactions…

Photo

HeadXNet

AI system helps radiologists detect brain aneurysms

Doctors could soon get some help from an artificial intelligence tool when diagnosing brain aneurysms—bulges in blood vessels in the brain that can leak or burst open, potentially leading to…

Related products

Agena Bioscience - MassARRAY Colon Panel

Amplification/Detection

Agena Bioscience - MassARRAY Colon Panel

Agena Bioscience GmbH
Agfa HealthCare – Dose

Dose Management Systems

Agfa HealthCare – Dose

Agfa HealthCare
Agfa HealthCare – DR 14e detector

DR Retrofit

Agfa HealthCare – DR 14e detector

Agfa HealthCare
Agfa HealthCare – DR 14s detector

DR Retrofit

Agfa HealthCare – DR 14s detector

Agfa HealthCare
Agfa HealthCare – DR 17e detector

DR Retrofit

Agfa HealthCare – DR 17e detector

Agfa HealthCare